Global Solid Tumor Partnering 2010-2015 - Reportlinker Review
The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.
NEW YORK, Oct. 21, 2015 /PRNewswire/ -- The Solid Tumor Cancer Partnering 2010-2015 report provides understanding and access to the solid tumor cancer partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in solid tumor cancer partnering deals
Top solid tumor cancer deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type
The Solid Tumor Cancer Partnering 2010-2015 provides understanding and access to the solid tumor cancer partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of solid tumor cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors solid tumor cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This data driven report contains over 200 links to online copies of actual solid tumor cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of solid tumor cancer partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.
Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.
Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.
Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bladder cancer technologies and products.
Report scope
Solid Tumor Cancer Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to solid tumor cancer trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
Trends in solid tumor cancer dealmaking in the biopharma industry since 2010
Access to summary headline, upfront, milestone and royalty data
Access to over 200 solid tumor cancer deals and contract documents whee available
The leading solid tumor cancer deals by value since 2010
In Solid Tumor Cancer Partnering 2010-2015, the available deals are listed by:
Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.Solid Tumor Cancer Partnering 2010-2015 provides the reader with the following key benefits:
In-depth understanding of solid tumor cancer deal trends since 2010
Access to summary headline, upfront, milestone and royalty data
Comprehensive access to over 200 actual solid tumor cancer deals entered into by the world's biopharma companies since 2010
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Read the full report: http://www.reportlinker.com/p03106573-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker reviews, finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article